Paraguay Medical Device Post-Market Compliance: Change Inspections and De Oficio Suspension (Article 15)

1. Key takeaways

1. Article 15: all changes to sanitary registrations and NSOs are subject to inspection and verification (fiscalizaciones), carried out by DINAVISA at random and according to risk analysis.
2. Consequence: if a change made after registration or after the NSO has not been reported, DINAVISA will suspend the market authorization de oficio until the correction is completed (Article 15).
3. Article 16: a change does not alter the expiry date, so time continues to run during a suspension, and the certificate is not extended because of it.
4. In combination with Article 29: if testing is required during an inspection, the cost is borne by the registration holder; for products without a certificate, the cost is borne by the importer or the manufacturer.

For imported portfolios, the practical consequence is that the local holder must be able to prove notification for changes made anywhere in the chain, including repackaging decisions taken abroad, so the notification duty should be written into supply agreements alongside the classification duties described in article 44 of this series.

2. Legal basis

The enforcement triangle formed by Articles 15, 16 and 29 is compact but complete. Article 15 creates the inspection duty and the de oficio suspension remedy, Article 16 removes any possibility of recovering lost time through an extension, and Article 29 prices the testing that an inspection may demand. Because a single instrument carries all three elements, the exposure of an unreported change can be evaluated arithmetically: lost sales for the duration of the suspension, no compensating extension of the certificate, and testing costs on top.

It is worth noting what Article 15 does not require: no prior warning, no request for explanation and no preliminary sanction decision precede the suspension. The measure attaches directly to the discovery of an unreported change. For planning purposes this means the response plan, covering who assembles the correction file, who informs distributors and who tracks the resumption of sales, must exist before the inspection, because there is no quiet phase in which to prepare one after the inspector arrives. Distributors and hospital customers feel the interruption immediately, so the communication plan matters as much as the regulatory one.

3. Expert insights

Insight one: random and risk-based means the inspection cannot be predicted, but it can be triggered. Article 15 states that inspections follow DINAVISA’s risk analysis and are carried out at random. A company cannot forecast the moment of an inspection, but it can lower its own probability profile by keeping the change notification record complete, keeping labels consistent with the certificate fields, and submitting vigilance reports on time. Risk-based selection rewards exactly the behaviors that are cheapest to maintain: a clean paper trail and disciplined filing lower the attractiveness of the file as an inspection target, while visible inconsistencies raise it.

Insight two: the suspension is de oficio and does not require a prior hearing or sanction proceeding. The provision uses the expression de oficio, which marks it as a precautionary measure rather than a punitive ruling. The practical meaning is that market access resumes when the correction is completed, but no sales are possible during the correction period, so the commercial loss is real and immediate. There is no separate adversarial process to lengthen the timeline before the suspension bites, which makes prevention dramatically cheaper than response. Teams should model the suspension scenario as a business-continuity risk, not merely as a regulatory fine print issue.

Companies should also note the interaction with the cost rules of Article 29: an inspection that uncovers an unreported change may also demand testing, and the testing costs fall on the registration holder. The financial exposure of a missed notification is therefore the sum of the suspension-period sales loss and the testing bill, not just one of the two.

Insight three: the label is the most common carrier of unreported changes found at inspection. The change table classifies appearance changes as Type I, implementable upon notification, but the notification obligation itself remains. A relabeled product that was never notified on the platform is immediately recognizable during an inspection (practical estimate: project experience). Because label changes are frequent and often driven by commercial teams rather than regulatory affairs, they are also the category where the notification step is most often skipped, making it the most frequent trigger of the Article 15 suspension mechanism.

4. Practical recommendations

1. Establish a mandatory linkage between physical change and platform notification: any revision of a label, package or instructions for use goes through the notification or authorization process before it is released, never after.
2. Run a periodic self-check comparing the platform fields, the certificate information and the physical label, on a semi-annual cycle, so that drift between the three is caught before an inspector catches it.
3. Preserve the complete record of change notifications, so that supporting evidence can be produced immediately during an inspection instead of being reconstructed under pressure.
4. If a suspension occurs, prioritize completing the correction and keep documented evidence of every corrective step, because the suspension lasts until the correction is completed and the quality of the evidence determines how quickly it ends.

The semi-annual three-way consistency check recommended above is deliberately simple. The comparison of platform fields, certificate data and physical labels takes an experienced reviewer only a few hours per portfolio, yet it addresses the single failure mode that leads to most de oficio suspensions. It also creates a written trail that demonstrates diligence if the company is ever inspected. Few compliance controls offer this ratio of effort to risk reduction.

5. Verification checklist

• □ A mandatory linkage between physical changes and platform notification has been established
• □ Consistency of platform fields, certificate and label is checked periodically
• □ Evidence of change notifications is fully preserved
• □ It is understood that the Article 15 suspension is a de oficio measure and does not extend validity
• □ The correction process and its owner are clearly defined

Regulatory information verified as of October 29, 2026.

GRZAN provides registration and post-market compliance support for medical device manufacturers, importers and authorized representatives in Paraguay. For assistance with inspection readiness, change compliance or any other regulatory matter, contact info@grzanglobal.com.